Related Stories

AbbVie’s migraine drug cleared for migraine attacks on NHS

pharminent June 10, 2026

Medicare Advantage in 2026: Enrollment Update and Key Trends

pharminent June 5, 2026

Medicare Advantage in 2026: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior Authorization

pharminent June 5, 2026

You May Have Missed

Aquipta recommended by NICE for acute migraine treatment

pharminent June 10, 2026

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

pharminent June 10, 2026

Lilly wins new FDA approval for eczema drug Ebglyss

pharminent June 10, 2026

Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug

pharminent June 10, 2026